Compare NTST & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | ANAB |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2017 |
| Metric | NTST | ANAB |
|---|---|---|
| Price | $20.16 | $52.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $20.27 | ★ $60.18 |
| AVG Volume (30 Days) | ★ 1.7M | 441.9K |
| Earning Date | 02-10-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $195,006,000.00 | $169,467,000.00 |
| Revenue This Year | $20.93 | $135.51 |
| Revenue Next Year | $10.80 | N/A |
| P/E Ratio | $245.16 | ★ N/A |
| Revenue Growth | 19.79 | ★ 196.42 |
| 52 Week Low | $13.74 | $13.99 |
| 52 Week High | $20.25 | $57.65 |
| Indicator | NTST | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 72.52 | 59.78 |
| Support Level | $18.70 | $46.85 |
| Resistance Level | $19.64 | $56.39 |
| Average True Range (ATR) | 0.48 | 3.61 |
| MACD | 0.11 | 0.48 |
| Stochastic Oscillator | 97.94 | 64.57 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).